港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

610.821

-11.772-1.89%

漲家數：3

跌家數：29

平家數：2

市盈率：- -

高：632.862

開：622.936

低：607.463

收：622.593

成交量：1.13億

成交額：25.31億

市值：3,894.69億

流通市值：3,473.89億

資料載入中...

總覽新聞資訊

榮昌生物(09995)出現大手賣出5.35萬股，成交價$95.0，涉資508.25萬

阿斯达克财经

港股異動 | 醫藥外包概念走強，昭衍新藥績後升逾13%，凱萊英升逾11%

老虎资讯综合

A股開盤速遞 | 三大指數升跌不一白酒板塊快速拉升創新藥概念反覆活躍

智通财经网

貝康醫療-B(02170)發布年度業績，收入2.33億元核心產品註冊、國產化推進及平台型業務佈局方面取得多項重要進展

微創心通-B(02160)發布年度業績股東應占虧損1881.9萬元按年擴大170.85%

華昊中天醫藥-B(02563)股份全流通獲聯交所授出上市批准

《業績》開拓藥業(09939.HK)全年虧損擴至2億人民幣

阿斯达克财经

康希諾生物(06185)公布2025年業績實現收入約10.59億元按年增長28.43%

和鉑醫藥-B(02142)公布2025年業績税後溢利9222.1萬美元按年增長約32.63倍

億騰嘉和(06998)3月30日斥資65.88萬港元回購25.45萬股

歐康維視生物-B(01477)：OT-211 III期臨床試驗完成首例患者入組

和鉑醫藥-B公布2025財年業績：持續全球合作夯實長期增長根基

和鉑醫藥公布2025年度業績：常態化全球合作構築業績增長基石

牛散趙建平連續重倉！創新藥迎來配置時點！

歸創通橋(02190)3月30日耗資約113.73萬港元回購4.8萬股

Wellington Management Group LLP增持勁方醫藥-B(02595)約31.82萬股每股均價約30.88港元

跨國巨頭密集押注+創新藥企盈利兑現，創新藥逆市走強，520880放量連陽！MIRXES-B狂飆43%

復宏漢霖(02696)：斯魯利單抗注射液獲歐洲藥品管理局人用醫藥產品委員會積極審評意見

阿斯利康(AZN)罕見病創新藥在華獲批

李氏大藥廠(00950)發布年度業績股東應占溢利9193.8萬港元按年減少1.2%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":610.8213,"timestamp":1774944503193,"preClose":622.5934,"halted":0,"volume":113424177,"delay":0,"changeRate":-0.018908,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":-11.772095,"latestTime":"03-31 16:00:00","open":622.93585,"high":632.86237,"low":607.46344,"amount":2531003032,"amplitude":0.040795,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1775007000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774920600000,1774929600000],[1774933200000,1774944000000]],"pbRate":4.922558,"peRate":-80.535923,"turnoverRate":0.003979,"increases":3,"decrements":30,"flats":0,"marketCap":389469309152,"floatMarketCap":347388785088},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":632.86237,"amplitude":0.040795,"preClose":622.5934,"low":607.46344,"pbRate":"4.922558","latestPrice":610.8213,"volume":113424177,"delay":0,"open":622.93585,"prevYearClose":556.26263,"prevWeekClose":606.745,"prevMonthClose":553.496,"prevQuarterClose":556.263,"fiveDayClose":567.335,"twentyDayClose":508.998,"sixtyDayClose":556.263,"secType":"PLATE","market":"HK","turnoverRate":0.003979,"peRate":-80.535923,"marketCap":389469309152,"floatMarketCap":347388785088,"timestamp":1774944503193,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":3,"down":29,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2623372639","title":"榮昌生物(09995)出現大手賣出5.35萬股，成交價$95.0，涉資508.25萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2623372639","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623372639?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 11:53","pubTimestamp":1774929180,"startTime":"0","endTime":"0","summary":"[大手成交]荣昌生物(09995)在上午11:53出现大手卖出，成交量为5.35万，成交价为港币$95.0，涉资508.25万。至目前为止，股价跌3.844%，今日最高价为$101.4，而最低价为$95.0，总成交量为265.4万股，总成交金额港币$2.569亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603314836/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603314836/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","09995","BK0239","LU2488822045.USD","688331","LU1064130708.USD","LU1969619763.USD","BK1574","BK1583","LU2148510915.USD","LU2328871848.SGD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109731579","title":"港股異動 | 醫藥外包概念走強，昭衍新藥績後升逾13%，凱萊英升逾11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109731579","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109731579?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 09:51","pubTimestamp":1774921897,"startTime":"0","endTime":"0","summary":"3月31日，医药外包概念走强，$昭衍新药(06127)$涨超13%，$凯莱英(06821)$涨超11%，$康龙化成(03759)$涨超6%，$药明生物(02269)$、$泰格医药(03347)$涨超5%","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821","LU1328615791.USD","BK1161","06127","BK4588","BK1191","09939","BK0239","BK1574","BK0216","BK1515","BK4585","BK1141","BK1576","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623376462","title":"A股開盤速遞 | 三大指數升跌不一 白酒板塊快速拉升 創新藥概念反覆活躍","url":"https://stock-news.laohu8.com/highlight/detail?id=2623376462","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623376462?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 09:51","pubTimestamp":1774921872,"startTime":"0","endTime":"0","summary":"3月31日，A股沪指高开0.02%，深成指低开0.31%，创业板指低开0.80%。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260331/20260331095128_13566.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260331/20260331095128_13566.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["159982","159992","06978","BK1161","BK1574","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623328501","title":"貝康醫療-B(02170)發布年度業績，收入2.33億元 核心產品註冊、國產化推進及平台型業務佈局方面取得多項重要進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2623328501","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623328501?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 01:24","pubTimestamp":1774891440,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B 发布截至2025年12月31日止年度业绩，该集团取得收入2.33亿元，同比减少22.01%;公司权益股东应占亏损2.23亿元，同比减少5.7%;每股亏损0.8元。2025年，对本集团而言，是由“研发及注册驱动”逐步迈向“商业化落地及经营优化驱动”的关键一年。报告期内，本集团在核心产品注册、国产化推进及平台型业务布局方面取得多项重要进展。于男科领域，家用精子检测设备获批上市，进一步完善本集团在辅助生殖前端检测场景的产品布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"贝康医疗-B(02170)发布年度业绩，收入2.33亿元 核心产品注册、国产化推进及平台型业务布局方面取得多项重要进展","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02170","BK1597","BK1574","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623340317","title":"微創心通-B(02160)發布年度業績 股東應占虧損1881.9萬元 按年擴大170.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623340317","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623340317?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 00:48","pubTimestamp":1774889327,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微创心通-B(02160)发布截至2025年12月31日止年度业绩，收入5704.4万美元，同比增加12.28%;股东应占亏损1881.9万元，同比扩大170.85%;每股基本亏损0.04美元。公告称，收入增长主要是由于集团自2025年12月19日起合并微创®心律管理后自CRM业务录得收入;及随着VitaFlow Liberty®自由•维心流TM及Alwide® Plus敖广®Plus全球商业化持续推进，结构性心脏病业务海外收入较截至2024年12月31日止年度快速增长 255.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"微创心通-B(02160)发布年度业绩 股东应占亏损1881.9万元 同比扩大170.85%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02160","BK1225","BK1583","BK1100","02918","BK1239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623347972","title":"華昊中天醫藥-B(02563)股份全流通獲聯交所授出上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2623347972","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623347972?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 00:26","pubTimestamp":1774888017,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华昊中天医药-B(02563)发布公告，公司已向联交所上市委员会申请批准将由1.48亿股非上市股份转换所得的1.48亿股H股上市及准许买卖。董事会欣然宣布，联交所已于2026年3月20日授出上市批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","BK1574","BK1161","159938","02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623134760","title":"《業績》開拓藥業(09939.HK)全年虧損擴至2億人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2623134760","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623134760?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 00:17","pubTimestamp":1774887420,"startTime":"0","endTime":"0","summary":"开拓药业－Ｂ(09939.HK) 公布2025年度业绩，收入录得3,262万人民币(下同)，按年增加553.6%。亏损由上年度1.55亿元，扩至2亿元，每股亏损44分。不派末期息。(de/d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2025/08/28中期业绩无派息2025/03/26末期业绩无派息2024/08/26中期业绩无派息2024/03/28末期业绩无派息AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200511160928560_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200511160928560_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1514353/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1514353/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09939","BK1161","CYB","CNHmain","MCNHmain","BK1515","BK1574","MUCmain","UCmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623478333","title":"康希諾生物(06185)公布2025年業績 實現收入約10.59億元 按年增長28.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623478333","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623478333?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 00:07","pubTimestamp":1774886865,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 公布2025年业绩，收入约10.59亿元，同比增长28.43%;年内利润2787.3万元，同比扭亏为盈;每股盈利0.11元。自2022年推出四价流脑结合疫苗曼海欣和二价流脑结合疫苗美奈喜以来，两款疫苗为预防婴幼儿流脑疾病提供了更为高效、优质的疫苗选择。2025年，随着流脑疫苗产品的推广和市场导入，两款流脑结合疫苗实现销售收入约9.677亿元，同比增长21.9%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物(06185)公布2025年业绩 实现收入约10.59亿元 同比增长28.43%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06185","BK1515","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623434187","title":"和鉑醫藥-B(02142)公布2025年業績 税後溢利9222.1萬美元 按年增長約32.63倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2623434187","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623434187?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 22:49","pubTimestamp":1774882160,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)公布2025年业绩，收入约1.58亿美元，同比增长314.63%;年内溢利9222.1万美元，同比增长约32.63倍;基本每股盈利0.12美元。于2025年，公司全面迈入3.0战略阶段，由三大增长引擎协同驱动：将诺纳生物打造为AI驱动的全球抗体药物发现“新基建”;与跨国制药公司建立长期、平台化的战略合作伙伴关系，以加速全球扩张;通过Harbour Therapeutics实现在自免、肿瘤等领域的中后期资产全球价值的最大化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"和铂医药-B(02142)公布2025年业绩 税后溢利9222.1万美元 同比增长约32.63倍","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623834675","title":"億騰嘉和(06998)3月30日斥資65.88萬港元回購25.45萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623834675","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623834675?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 22:16","pubTimestamp":1774880212,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿腾嘉和(06998)发布公告，于2026年3月30日斥资65.88万港元回购25.45万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","06998","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623346987","title":"歐康維視生物-B(01477)：OT-211 III期臨床試驗完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2623346987","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623346987?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 22:05","pubTimestamp":1774879506,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，OT-211 在中国开展的III期临床试验已完成首例患者入组。OT-211 为一种 0.003%浓度滴眼液配方，亦为首款获美国食品药品监督管理局批准用于治疗干眼症的TRPM8激动剂。首例患者成功入组标志着OT-211在中国的临床开发取得重要里程碑进展，并体现了集团致力于为DED患者推进创新疗法。OT-211 已于2025年5月 28日获FDA批准用于治疗DED的体征及症状。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1191","BK1574","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193648759","title":"和鉑醫藥-B公布2025財年業績：持續全球合作夯實長期增長根基","url":"https://stock-news.laohu8.com/highlight/detail?id=1193648759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193648759?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 21:55","pubTimestamp":1774878918,"startTime":"0","endTime":"0","summary":"和铂医药-B发布2025财年完整财务报告，显示公司通过持续深化的全球战略合作，为长期可持续发展奠定了坚实基础。全球多中心临床研究项目稳步推进，跨境技术平台协同效应显著增强，共同推动创新管线价值加速释放。公司管理层表示，将继续依托自主知识产权的抗体技术平台，构建开放共赢的全球创新生态。亚洲及欧美市场临床数据持续产出，为后续商业化提供强有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623858349","title":"和鉑醫藥公布2025年度業績：常態化全球合作構築業績增長基石","url":"https://stock-news.laohu8.com/highlight/detail?id=2623858349","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623858349?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 21:53","pubTimestamp":1774878780,"startTime":"0","endTime":"0","summary":"未来，和铂医药将持续深化源头创新，加速助力新一代生物疗法研发，为全球患者带来变革性疗法。此外，公司于2024年11月向NMPA递交HBM9378针对慢性阻塞性肺疾病的IND申请，并于2025年1月获得批准。2025年7月，Windward Bio启动全球II期POLARIS临床研究，旨在评估 HBM9378/WIN378 的长效给药方式对哮喘患者的疗效。2025年12月，NMPA受理了HBM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4921935_ZH21935_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK1574","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623457310","title":"牛散趙建平連續重倉！創新藥迎來配置時點！","url":"https://stock-news.laohu8.com/highlight/detail?id=2623457310","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623457310?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 20:35","pubTimestamp":1774874100,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　今日，A股市场迎来结构性行情，医药板块率先发力，成为当日市场最具活力的赛道之一。　　2月8日，信达生物宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。如盟科药业的前十大股东中则继续出现了赵建平与赵吉的身影，这已是赵建平、赵吉连续5个季度对公司公开重仓。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-03-30/doc-inhsuquq3871370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1161","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623317007","title":"歸創通橋(02190)3月30日耗資約113.73萬港元回購4.8萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623317007","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623317007?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 20:25","pubTimestamp":1774873551,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)公布，2026年3月30日耗资约113.73万港元回购4.8万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02190","BK1583","BK1100","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314171","title":"Wellington Management Group LLP增持勁方醫藥-B(02595)約31.82萬股 每股均價約30.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314171","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314171?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 19:25","pubTimestamp":1774869941,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，3月26日，Wellington Management Group LLP增持劲方医药-B(02595)31.8247万股，每股均价30.8754港元，总金额约为982.60万港元。增持后最新持股数目约为2374.17万股，持股比例为7.02%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","02595","BK1161","EWH","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623110253","title":"跨國巨頭密集押注+創新藥企盈利兑現，創新藥逆市走強，520880放量連陽！MIRXES-B狂飆43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623110253","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623110253?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 19:10","pubTimestamp":1774869000,"startTime":"0","endTime":"0","summary":"3月30日，A港市场调整为主，创新药再度走出独立行情！100%创新药研发标的——港股通创新药ETF华宝、重仓A股创新药的药ETF逆市续涨逾1%，上一交易日，两只ETF单日大涨5.51%、4.21%，双双创下历史最大单日涨幅。　　聚焦港股通创新药日内表现，板块代表性港股通创新药ETF华宝低开高走，一度上探逾2%，最终放量收涨1%顺利连阳，全天振幅达3.61%，成交7.81亿元，续刷4个半月来新高！MIRXES-B午后突然狂飙逾43%，收涨23.69%%！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-30/doc-inhsukns3956006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","520880","159992","02629","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315758","title":"復宏漢霖(02696)：斯魯利單抗注射液獲歐洲藥品管理局人用醫藥產品委員會積極審評意見","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315758","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315758?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 17:58","pubTimestamp":1774864728,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，公司自主开发的斯鲁利单抗注射液(汉斯状) 获欧洲药品管理局人用医药产品委员会积极审评意见。CHMP的审评意见将会被递交至欧盟委员会， EC将参考该意见并在未来2个月内做出最终审查决定。一旦获得EC 批准，汉斯状的集中上市许可将在所有欧盟成员国及欧洲经济区国家冰岛、列支敦士登和挪威生效。此次CHMP的积极意见主要是基于两项随机、双盲、多中心3期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320223.HKD","BK1515","HK0000306701.USD","HK0000306685.HKD","02696","HK0000165453.HKD","BK1574","159938","HK0000320264.USD","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623154273","title":"阿斯利康(AZN)罕見病創新藥在華獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2623154273","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623154273?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 17:55","pubTimestamp":1774864518,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康(AZN)宣布，中国国家药品监督管理局已正式批准硫酸氢司美替尼胶囊（商品名：科赛优），用于3岁及3岁以上伴有症状、无法手术的丛状神经纤维瘤（PN）的1型神经纤维瘤病（NF1）儿童及成人患者的治疗。这是目前国内首个且唯一获批用于3岁及3岁以上该患者人群的治疗药物。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298501","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2462157665.USD","BK4568","LU0109394709.USD","IE00B3T34201.USD","LU0320765992.SGD","BK4007","LU0289739699.SGD","BK4588","LU2236285917.USD","LU0058720904.USD","BK4585","AZN","LU2417539215.USD","BK1574","159992","LU0889565916.HKD","LU2456880835.USD","LU1829250122.USD","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623318798","title":"李氏大藥廠(00950)發布年度業績 股東應占溢利9193.8萬港元 按年減少1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623318798","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623318798?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 17:19","pubTimestamp":1774862354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布截至2025年12月31日止年度业绩，集团收益14.36亿港元，同比增长2.6%;股东应占溢利9193.8万港元，同比减少1.2%;每股盈利15.61港仙;拟派末期股息每股2.3港仙。公告称，公司拥有人应占纯利减少反映严峻市场环境及研发支出增加的合并影响，抵销了收益增长及销售费用减少所带来的裨益，导致纯利同比下滑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00950","BK1191","BK1574","06622","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":2,"totalSize":336,"code":"91000000","status":"200"}]}}